School of Life Science and Technology, China Pharmaceutical University, Nanjing, China.
PLoS One. 2012;7(8):e43075. doi: 10.1371/journal.pone.0043075. Epub 2012 Aug 17.
Epidemiologic findings are inconsistent concerning the associations between C-reactive protein (CRP), interleukin 6 (IL-6) and lung cancer risk. We conducted a meta-analysis of epidemiologic studies to examine these associations.
A systematic literature search up to October 2011 was performed in MEDLINE and EMBASE. Study-specific risk estimates were pooled using a random-effects model.
The 10 studies on CRP involved a total of 1918 lung cancer cases. The pooled RR of lung cancer for one unit change in natural logarithm (ln) CRP was 1.28 (95% CI 1.17-1.41). There was no statistically significant heterogeneity among studies (P = 0.116; I(2) = 36.6%). We also found that CRP was significantly associated with increased risk of lung cancer among men (RR 1.18, 95% CI 1.09-1.28) but not among women. The 5 studies on IL-6 involved a total of 924 lung cancer cases. The pooled RR of lung cancer for one unit change in ln IL-6 was 1.28 (95% CI 0.92-1.79), however, statistically significant heterogeneity was found. After excluding the study contributing most to the heterogeneity, the summary estimate was essentially unchanged.
CRP was associated with increased risk of lung cancer, especially among men. There was no significant association between IL-6 and lung cancer risk.
关于 C 反应蛋白(CRP)、白细胞介素 6(IL-6)与肺癌风险之间的关联,流行病学研究结果并不一致。我们进行了一项荟萃分析,以检查这些关联。
对 MEDLINE 和 EMBASE 进行了系统的文献检索,直至 2011 年 10 月。使用随机效应模型汇总研究特异性风险估计值。
10 项关于 CRP 的研究共涉及 1918 例肺癌病例。lnCRP 每增加一个单位,肺癌的 RR 为 1.28(95%CI 1.17-1.41)。研究之间无统计学显著异质性(P = 0.116;I² = 36.6%)。我们还发现 CRP 与男性肺癌风险增加显著相关(RR 1.18,95%CI 1.09-1.28),但与女性无关。5 项关于 IL-6 的研究共涉及 924 例肺癌病例。lnIL-6 每增加一个单位,肺癌的 RR 为 1.28(95%CI 0.92-1.79),但存在统计学显著异质性。排除对异质性贡献最大的研究后,汇总估计值基本不变。
CRP 与肺癌风险增加相关,尤其是在男性中。IL-6 与肺癌风险之间无显著关联。